

Study Number: 108020006
Test Type: 5-Day Toxicity
Route: Whole-Body Inhalation
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: 1,2-Dichlorobenzene
CAS Number: 95-50-1

Date Report Requested: 09/26/2025
Time Report Requested: 15:37:47
Lab: Battelle

Study Number: 108020006
Study Sex: Female
PWG Approval Date: See web page for date of PWG Approval
Version: v1.7.2-6-ge85fa364
Stat Version: 2023.02.27S

Study Number: 108020006

Test Type: 5-Day Toxicity

Route: Whole-Body Inhalation

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: 1,2-Dichlorobenzene

CAS Number: 95-50-1

Date Report Requested: 09/26/2025

Time Report Requested: 15:37:47

Lab: Battelle

Female: Core Animals

	Phase Day	Treatment Groups (ppm)				
		0	1	10	30	100
Urea Nitrogen (mg/dL)	SD 5	15.3 ± 0.4 (10)	16.2 ± 0.6 (5)	14.4 ± 0.7 (5)	14.4 ± 0.5 (5)	15.0 ± 1.0 (5)
Percent of Control			105.9	94.1	94.1	98.0
Creatinine (mg/dL)	SD 5	0.38 ± 0.02 (10) *	0.42 ± 0.02 (5)	0.38 ± 0.02 (5)	0.40 ± 0.00 (5)	0.34 ± 0.02 (5)
Percent of Control			110.5	100.0	105.3	89.5
Glucose (mg/dL)	SD 5	135.0 ± 6.7 (10) **	144.6 ± 6.1 (5)	129.8 ± 1.8 (5)	135.0 ± 6.4 (5)	127.8 ± 2.5 (5)
Percent of Control			107.1	96.1	100.0	94.7
Total Protein (g/dL)	SD 5	6.50 ± 0.08 (10)	6.50 ± 0.12 (5)	6.46 ± 0.14 (5)	6.72 ± 0.17 (5)	6.54 ± 0.16 (5)
Percent of Control			100.0	99.4	103.4	100.6
Globulin (g/dL)	SD 5	1.63 ± 0.06 (10) *	1.58 ± 0.04 (5)	1.64 ± 0.07 (5)	1.80 ± 0.11 (5)	1.62 ± 0.07 (5)
Percent of Control			96.9	100.6	110.4	99.4
A/G Ratio	SD 5	3.02 ± 0.11 (10) **	3.12 ± 0.07 (5)	2.96 ± 0.14 (5)	2.78 ± 0.19 (5)	3.06 ± 0.12 (5)
Percent of Control			103.3	98.0	92.0	101.2
Albumin (g/dL)	SD 5	4.87 ± 0.06 (10)	4.92 ± 0.10 (5)	4.82 ± 0.11 (5)	4.92 ± 0.14 (5)	4.92 ± 0.10 (5)
Percent of Control			101.0	99.0	101.0	101.0
Cholesterol (mg/dL)	SD 5	87.7 ± 2.8 (10) **	89.0 ± 2.8 (5)	82.6 ± 0.7 (5)	93.8 ± 7.5 (5)	97.0 ± 3.2 (5)
Percent of Control			101.5	94.2	107.0	110.6
Triglyceride (mg/dL)	SD 5	75.1 ± 8.3 (10)	62.8 ± 5.1 (5)	64.8 ± 11.4 (4)	74.8 ± 9.4 (5)	52.4 ± 5.7 (5)
Percent of Control			83.6	86.2	99.6	69.8
Alanine Aminotransferase (IU/L)	SD 5	45.9 ± 1.3 (10)	42.4 ± 2.0 (5)	44.3 ± 3.4 (4)	49.8 ± 1.2 (5)	44.6 ± 3.0 (5)
Percent of Control			92.4	96.4	108.5	97.2
Alkaline Phosphatase (IU/L)	SD 5	248.8 ± 13.7 (10)	223.2 ± 8.5 (5)	239.8 ± 10.4 (5)	242.8 ± 18.0 (5)	238.0 ± 7.2 (5)
Percent of Control			89.7	96.4	97.6	95.7

Study Number: 108020006

Test Type: 5-Day Toxicity

Route: Whole-Body Inhalation

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: 1,2-Dichlorobenzene

CAS Number: 95-50-1

Date Report Requested: 09/26/2025

Time Report Requested: 15:37:47

Lab: Battelle

Female: Core Animals

	Phase Day	Treatment Groups (ppm)				
		0	1	10	30	100
Aspartate Aminotransferase (U/L) Percent of Control	SD 5	77.20 ± 1.46 (10)	71.00 ± 3.15 (5) 92.0	80.60 ± 2.29 (5) 104.4	73.20 ± 2.08 (5) 94.8	70.80 ± 3.56 (5) 91.7
Creatine Kinase (IU/L) Percent of Control	SD 5	307.4 ± 37.2 (10)	266.8 ± 75.5 (5) 86.8	565.2 ± 106.1 (5) 183.9	331.8 ± 35.6 (5) 107.9	375.0 ± 81.8 (5) 122.0
Sorbitol Dehydrogenase (IU/L) Percent of Control	SD 5	11.9 ± 1.2 (10)	9.4 ± 1.0 (5) 78.8	10.4 ± 0.9 (5) 87.2	8.7 ± 1.6 (5) 73.2	8.7 ± 1.2 (5) 73.0
Bile salt/acids (µmol/L) Percent of Control	SD 5	6.0 ± 1.3 (10) **	4.6 ± 0.8 (5) 76.7	9.3 ± 3.0 (4) 154.2	13.6 ± 3.8 (5) 226.7	15.2 ± 5.5 (5) 253.3

Study Number: 108020006

Test Type: 5-Day Toxicity

Route: Whole-Body Inhalation

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: 1,2-Dichlorobenzene

CAS Number: 95-50-1

Date Report Requested: 09/26/2025

Time Report Requested: 15:37:47

Lab: Battelle

Female: Core Animals

	Phase Day	Treatment Groups (ppm)	
		250	500
Urea Nitrogen (mg/dL)	SD 5	12.6 ± 1.0 (5)	17.6 ± 1.3 (5)
Percent of Control		82.4	115.0
Creatinine (mg/dL)	SD 5	0.32 ± 0.02 (5)	0.34 ± 0.02 (5)
Percent of Control		84.2	89.5
Glucose (mg/dL)	SD 5	130.2 ± 15.6 (5)	104.8 ± 2.4 (5) **
Percent of Control		96.4	77.6
Total Protein (g/dL)	SD 5	6.38 ± 0.12 (5)	6.36 ± 0.16 (5)
Percent of Control		98.2	97.8
Globulin (g/dL)	SD 5	1.46 ± 0.06 (5)	1.36 ± 0.06 (5)
Percent of Control		89.6	83.4
A/G Ratio	SD 5	3.39 ± 0.11 (5)	3.69 ± 0.11 (5) **
Percent of Control		112.2	122.4
Albumin (g/dL)	SD 5	4.92 ± 0.07 (5)	5.00 ± 0.11 (5)
Percent of Control		101.0	102.7
Cholesterol (mg/dL)	SD 5	94.8 ± 5.4 (5)	134.8 ± 8.1 (5) **
Percent of Control		108.1	153.7
Triglyceride (mg/dL)	SD 5	70.2 ± 8.2 (5)	85.8 ± 20.4 (5)
Percent of Control		93.5	114.2
Alanine Aminotransferase (IU/L)	SD 5	47.4 ± 3.0 (5)	46.4 ± 4.9 (5)
Percent of Control		103.3	101.1
Alkaline Phosphatase (IU/L)	SD 5	298.6 ± 35.1 (5)	254.4 ± 17.6 (5)
Percent of Control		120.0	102.3

Study Number: 108020006

Test Type: 5-Day Toxicity

Route: Whole-Body Inhalation

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: 1,2-Dichlorobenzene

CAS Number: 95-50-1

Date Report Requested: 09/26/2025

Time Report Requested: 15:37:47

Lab: Battelle

Female: Core Animals

	Phase Day	Treatment Groups (ppm)	
		250	500
Aspartate Aminotransferase (U/L)	SD 5	73.40 ± 2.01 (5)	109.00 ± 18.71 (5)
Percent of Control		95.1	141.2
Creatine Kinase (IU/L)	SD 5	389.8 ± 75.6 (5)	334.4 ± 84.6 (5)
Percent of Control		126.8	108.8
Sorbitol Dehydrogenase (IU/L)	SD 5	10.8 ± 2.7 (5)	43.2 ± 12.5 (5)
Percent of Control		90.7	362.6
Bile salt/acids (µmol/L)	SD 5	23.0 ± 5.6 (5) **	42.4 ± 12.6 (5) **
Percent of Control		383.3	706.7

Study Number: 108020006

Test Type: 5-Day Toxicity

Route: Whole-Body Inhalation

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: 1,2-Dichlorobenzene

CAS Number: 95-50-1

Date Report Requested: 09/26/2025

Time Report Requested: 15:37:47

Lab: Battelle

LEGEND

Values given as mean \pm SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100.

SD = Study Day

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test.

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group.

* Statistically significant at $p \leq 0.05$

** Statistically significant at $p \leq 0.01$

Control and some treated animals' total and direct bilirubin values were below linearity, consistent with normal baseline concentrations. The number of samples that were above linearity was low, thus no statistical analysis was conducted for these endpoints.

Clinical chemistry data not reported was removed as an outlier, or was due to pre-analytical or analytical conditions or errors including but not limited to: below linearity, short sample, quantity not sufficient, or extreme hemolysis.

**** END OF REPORT ****